SCHEMBL17834370

SCHEMBL17834370

C[C@@H](NC(=O)[C@H](Cc1ccc(-c2ncc(-c3ccc(O)c(F)c3)cn2)cc1)NC(=O)c1ccc(C(C)(C)C)s1)C(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.36
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36
MME P08473 1/20 0.32
MAPT P10636 3/20 0.32
NPSR1 Q6W5P4 2/20 0.32
POLB P06746 2/20 0.32
RECQL P46063 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
LY96 Q9Y6Y9 1/20 0.32
CTSS P25774 3/20 0.32
CTSK P43235 3/20 0.32
LIPC P11150 1/20 0.32
LIPG Q9Y5X9 1/20 0.32
KIFC1 Q9BW19 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
ATM Q13315 1/20 0.32
HDAC1 Q13547 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17825474 0.91 MME (0.36) MMELIPGKIFC1
SCHEMBL19465500 0.91 MME (0.36) MMELIPGKIFC1
SCHEMBL16305783 0.90 TDP1 (0.39) TDP1MAPTNPSR1POLBRECQL
SCHEMBL22756207 0.90 TDP1 (0.39) TDP1MAPTNPSR1POLBRECQL
SCHEMBL17834530 0.89 ALOX5AP (0.40) TDP1ALOX5APFEN1MMEMAPT
SCHEMBL17834371 0.88 TDP1 (0.35) TDP1ALOX5APFEN1MAPTPOLB
SCHEMBL22167206 0.87 TDP1 (0.41) TDP1MMEMAPTNPSR1POLB
SCHEMBL17459588 0.87 TDP1 (0.41) TDP1MMEMAPTNPSR1POLB
SCHEMBL17459587 0.87 TDP1 (0.41) TDP1MMEMAPTNPSR1POLB
SCHEMBL16305782 0.87 TDP1 (0.41) TDP1MMEMAPTNPSR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 EP disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 US disclosed
WO-2016094729-A1 GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R TDP1 3121/4885ALOX5AP 3115/4885FEN1 3722/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R TDP1 3121/4885ALOX5AP 3115/4885FEN1 3722/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR TDP1 3259/4885ALOX5AP 3438/4885FEN1 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.